Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Genprex, Inc. GNPX

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$-16.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income -21.1
-15M-30M
2016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -338.7%
-200%-400%
201620202025
Three returns, three denominators.

Each USD of equity lost 339 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -17.6
-10M-20M
201620202025

Total assetsUSD 10.2M
EquityUSD 8.0M
CashUSD 7.8M
Current ratio3.84×

Equity funds 78% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
GNPX, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B◌0.00.00.00.00.0◌0.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.0◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $◌◌◌◌−0.42−0.51−0.66−0.90−0.29−0.38
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−338.7−467.2−207.9−74.7−57.2−105.7−179.0−265.8−322.8−254.3
Shares out B0.000.010.000.050.050.040.020.020.010.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 40 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Nine checks were skipped: EPS is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inTexas
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image